Cargando…
Sézary syndrome patient–derived models allow drug selection for personalized therapy
Current therapeutic approaches for Sézary syndrome (SS) do not achieve a significant improvement in long-term survival of patients, and they are mainly focused on reducing blood tumor burden to improve quality of life. Eradication of SS is hindered by its genetic and molecular heterogeneity. Determi...
Autores principales: | Gallardo, Fernando, Andrades, Evelyn, Iglesias, Arnau, González, Jessica, Solé, Laura, Guillén, Yolanda, Blanco, Gonzalo, Colomo, Luis, Gimeno, Eva, Conde, David, Rodriguez, Eva, Bielsa-Marso, Isabel, Iglesias, Mar, Bellosillo, Beatriz, Pujol, Ramon M., Regueiro, José R., Bigas, Anna, Espinosa, Lluís |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9198935/ https://www.ncbi.nlm.nih.gov/pubmed/35413113 http://dx.doi.org/10.1182/bloodadvances.2021006860 |
Ejemplares similares
-
Sézary syndrome originates from heavily mutated hematopoietic progenitors
por: Harro, Carly M., et al.
Publicado: (2023) -
Evaluation of 4 prognostic indices in follicular lymphoma treated in first line with immunochemotherapy
por: Rodríguez-Sevilla, Juan Jose, et al.
Publicado: (2022) -
CD158k and PD-1 expressions define heterogeneous subtypes of Sezary syndrome
por: Vergnolle, Inès, et al.
Publicado: (2022) -
Single-cell analysis of Sézary syndrome reveals novel markers and shifting gene profiles associated with treatment
por: Borcherding, Nicholas, et al.
Publicado: (2022) -
Enhanced systemic antilymphoma immune response by photothermal therapy with CpG deoxynucleotide–coated nanoparticles
por: Lin, Adam Yuh, et al.
Publicado: (2022)